Back to search results

A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy

Abroad (travel likely)RecruitingPHASE2

Conditions

Immunoglobulin A Nephropathy · Kidney Diseases · Glomerulonephritis, IGA · Glomerulonephritis · Autoimmune Diseases · Immune System Diseases

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Cambridge University Hospitals NHS Trust, Cambridge, England, United Kingdom

  • Northern Care Alliance NHS Foundation Trust - Salford Royal, Salford, England, United Kingdom

  • Royal Infirmary of Edinburgh & Western General Hospital, Edinburgh, Scotland, United Kingdom

  • University Hospital of wales, Cardiff, Wales, United Kingdom

  • Leicester General Hospital, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom

    Contact: Study coordinator (Justyna Szklarzewicz) · justyna.szklarzewicz@uhl-tr.nhs.uk · +44 116 258 4351
    Contact: Principal Investigator (Chee Kay Cheung, MBChB PhD)

  • King's College Hospital, London, United Kingdom

Study leads

  • Chee Kay Cheung, MBChB PhD

    Principal Investigator

    University of Leicester

View source on ClinicalTrials.gov(opens in a new tab)